Literature DB >> 15526378

Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line.

Jian Guan1, Xiao-Ping Chen, Hong Zhu, Shun-Feng Luo, Bin Cao, Lei Ding.   

Abstract

AIM: To investigate the molecular mechanism of the influence of HBx protein on multidrug resistance associated genes: multidrug resistance 1 (MDR-1), multidrug related protein (MRP-1), lung resistance related protein (LRP) in hepatoma cells and the potential role of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway in this process.
METHODS: A cell model stably expressing the HBx protein was established by liposome-mediated transfection of HBx gene into HepG2 cell line. The expression of multidrug resistance associated genes and proteins was detected by RT-PCR and Western blot. AnnexinV-FITC/PI assay was used to confirm the multidrug resistance (MDR) phenotype of transfected cells by fluorescence cytometry (FACS). The ERK/MAPK pathway activation was measured by Western blot through comparing the ratio of phosphorylation of ERK/MAPK to total ERK/MAPK protein. After treated with the ERK/MAPK pathway inhibitor U0126, the HBx-expressing cells were harvested. Then RT-PCR, Western blot and FACS were used to analyze the alterations in the expression of multidrug resistance associated genes and the MDR phenotype after exposure.
RESULTS: Compared with the control group, the transfected cells showed a higher expression of MDR associated genes and proteins. Marked elevations in MDR-1 (64.3%), MRP-1 (87.5%) and LRP (90.8%) were observed in the transfected cells (P<0.05). RT-PCR revealed that the over-expression of MDR associated proteins was due to amplification of such genes (MDR1 2.9 fold, MRP1 1.67 fold, LRP1.95 fold). Furthermore, we found that the ERK/MAPK activity was remarkably high in the HBx-expressing cells. The activation of ERK/MAPK, as measured by the ratio of phosphorylated ERK bands normalized to the total ERK bands, was increased by 2.3-fold in HBx-transfected cells compared with cells transfected with the empty vector. After treated with the ERK/MAPK pathway inhibitor, the level of MDR associated genes and proteins in the transfected cells decreased to some extent. Compared with controls, a significant decrease in MDR-1 mRNA (53.3%), MRP-1 mRNA (59.7%) as well as LRP mRNA (56.4%) was observed in the U0126 treated transfected cells after 12 h. Western blot also demonstrated that the protein expression of these MDR associated genes slightly reduced after treated with U0126 for 12 h (MDR-1 40.1%, MRP-1 29.4%, LRP35.7%). This change was accompanied with the rise of cell apoptosis ratio confirmed by Annexin V-PI detection. The apoptosis index of U0126-treated cells increased by 1.28 fold, compared with that of transfected cells. Obviously, the MDR phenotype of these cells was obviously related with increased activities of the ERK/MAPK pathway.
CONCLUSION: HBx protein might be one of the causes for the occurrence of MDR in HCC, and ERK/MAPK pathway might be involved in this change.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526378      PMCID: PMC4576240          DOI: 10.3748/wjg.v10.i23.3522

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Authors:  F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

2.  Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses.

Authors:  Ralph Schuster; Eberhardt Hildt; Shau-Feng Chang; Olivier Terradillos; Teresa Pollicino; Robert Lanford; Wolfram H Gerlich; Hans Will; Stephan Schaefer
Journal:  Oncogene       Date:  2002-09-26       Impact factor: 9.867

3.  The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver.

Authors:  Olivier Terradillos; Alix de La Coste; Teresa Pollicino; Christine Neuveut; Delphine Sitterlin; Hervé Lecoeur; Marie-Lise Gougeon; Axel Kahn; Marie-Annick Buendia
Journal:  Oncogene       Date:  2002-01-17       Impact factor: 9.867

Review 4.  Molecular cancer therapeutics: recent progress and targets in drug resistance.

Authors:  Takashi Tsuruo
Journal:  Intern Med       Date:  2003-03       Impact factor: 1.271

Review 5.  Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy.

Authors:  M Fan; T C Chambers
Journal:  Drug Resist Updat       Date:  2001-08       Impact factor: 18.500

6.  Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.

Authors:  R Nijhara; S S Jana; S K Goswami; A Rana; S S Majumdar; V Kumar; D P Sarkar
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 7.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

Review 8.  Strategies for reversing drug resistance.

Authors:  Tito Fojo; Susan Bates
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway.

Authors:  Chawon Yun; Hyeseon Cho; Su-Jeong Kim; Jae-Ho Lee; Sun Yi Park; Gordon K Chan; Hyeseong Cho
Journal:  Mol Cancer Res       Date:  2004-03       Impact factor: 5.852

10.  Cross-talk between signalling pathways and the multidrug resistant protein MDR-1.

Authors:  S Ding; M Chamberlain; A McLaren; L Goh; I Duncan; C R Wolf
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

View more
  13 in total

1.  Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.

Authors:  Shaymaa M M Yahya; Shadia A Fathy; Zakaria A El-Khayat; Safinaz E El-Toukhy; Ahmed R Hamed; Marwa G A Hegazy; Heba K Nabih
Journal:  Indian J Clin Biochem       Date:  2017-04-21

Review 2.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.

Authors:  Alex Y Strongin
Journal:  Biochim Biophys Acta       Date:  2009-05-04

Review 3.  Evolution of systemic therapy of advanced hepatocellular carcinoma.

Authors:  Thomas Yau; Pierre Chan; Richard Epstein; Ronnie-T Poon
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

4.  Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors.

Authors:  Bo Gao; Feng-Mei Yang; Zong-Tao Yu; Rui Li; Fei Xie; Jie Chen; Hai-Jun Luo; Ji-Cai Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Mol Cancer       Date:  2010-12-15       Impact factor: 27.401

6.  Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro.

Authors:  Katrin Hoffmann; Zhi Xiao; Clemens Franz; Elvira Mohr; Susanne Serba; Markus W Büchler; Peter Schemmer
Journal:  Cancer Cell Int       Date:  2011-11-17       Impact factor: 5.722

7.  Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling.

Authors:  Yiting Wang; Jing Cai; Xiaoli Zeng; Yajie Chen; Wei Yan; Yuming Ouyang; Dan Xiao; Zhiming Zeng; Long Huang; Anwen Liu
Journal:  BMC Cancer       Date:  2015-10-30       Impact factor: 4.430

8.  Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity.

Authors:  Siyuan Chen; Yali Wang; Wenwen Ruan; Xiaomin Wang; Chao Pan
Journal:  Oncol Lett       Date:  2014-09-10       Impact factor: 2.967

9.  Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.

Authors:  Yong Tang; Fenghua Liu; Chunning Zheng; Shaochuan Sun; Yingsheng Jiang
Journal:  J Exp Clin Cancer Res       Date:  2012-09-11

Review 10.  Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections.

Authors:  Upal Roy; Paul Barber; Yuk-Ching Tse-Dinh; Elena V Batrakova; Debasis Mondal; Madhavan Nair
Journal:  Front Microbiol       Date:  2015-09-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.